Evidence map›Paper›PMID 35924598›Full record

ArticleActa crystallographica. Section F, Structural biology communications2022

Crystal structures of glutamyl-tRNA synthetase from Elizabethkingia anopheles and E. meningosepticum.

Lauryn Brooks, Sandhya Subramanian, David M Dranow, Stephen J Mayclin, Peter J Myler, Oluwatoyin A Asojo

Abstract read
In one paragraph

Article in Acta crystallographica. Section F, Structural biology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Architecture ofProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Crystal structure of glutamyl-tRNA synthetase from Helicobacter pylori.Acta crystallographica. Section F, Structural biology communications · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lauryn BrooksDepartment of Chemistry and Biochemistry, Hampton University, Hampton, VA 23668, USA.ORCID 0000-0003-1088-9248
Sandhya SubramanianCenter for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North Suite 500, Seattle, WA 98109, USA.
David M DranowSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington, USA.ORCID 0000-0003-1871-2455
Stephen J MayclinSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington, USA.ORCID 0000-0002-1600-4554
Peter J MylerCenter for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North Suite 500, Seattle, WA 98109, USA.ORCID 0000-0002-0056-0513
Oluwatoyin A AsojoDepartment of Chemistry and Biochemistry, Hampton University, Hampton, VA 23668, USA.ORCID 0000-0002-4043-2700

Funding

U-RISE at Hampton UniversityT34GM136489 · NIGMS · HAMPTON UNIVERSITY · PI EREBHOLO, FRANCIS, NJOKI, PETER · 2020 to 2024
$1.5M
HU-CHEM: Deploying evidence-based interventions in Chemistry at Hampton University to plug leaks in the biomedical training pipelineU01GM138433 · NIGMS · HAMPTON UNIVERSITY · PI ASOJO, OLUWATOYIN AJIBOLA · 2020 to 2022
$1.1M
National Institute of Allergy and Infectious Diseases 1U01GM138433National Institute of Allergy and Infectious Diseases T34GM136489NIAID NIH HHS HHSN272200700057CNIAID NIH HHS HHSN272201200025CNIAID NIH HHS HHSN272201700059CNIGMS NIH HHS T34 GM136489NIGMS NIH HHS U01 GM138433
6 · The paper itself

Abstract

Elizabethkingia bacteria are globally emerging pathogens that cause opportunistic and nosocomial infections, with up to 40% mortality among the immunocompromised. Elizabethkingia species are in the pipeline of organisms for high-throughput structural analysis at the Seattle Structural Genomics Center for Infectious Disease (SSGCID). These efforts include the structure-function analysis of potential therapeutic targets. Glutamyl-tRNA synthetase (GluRS) is essential for tRNA aminoacylation and is under investigation as a bacterial drug target. The SSGCID produced, crystallized and determined high-resolution structures of GluRS from E. meningosepticum (EmGluRS) and E. anopheles (EaGluRS). EmGluRS was co-crystallized with glutamate, while EaGluRS is an apo structure. EmGluRS shares ∼97% sequence identity with EaGluRS but less than 39% sequence identity with any other structure in the Protein Data Bank. EmGluRS and EaGluRS have the prototypical bacterial GluRS topology. EmGluRS and EaGluRS have similar binding sites and tertiary structures to other bacterial GluRSs that are promising drug targets. These structural similarities can be exploited for drug discovery.

Indexed as

AnophelesFlavobacteriaceae InfectionsAmino Acid SequenceAnimalsCrystallography, X-RayGlutamate-tRNA LigaseGlutamate-tRNA LigaseElizabethkingia anophelesElizabethkingia meningosepticumemerging infectious diseasesglutamyl-tRNA synthetasesinfectious diseasesSeattle Structural Genomics Center for Infectious Diseaseundergraduate education and training

Identifiers

PMID35924598
PMCPMC9350836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.